IP Library Granted Patent US 10,463,727
Granted Patent B2
US 10,463,727 · App. 15/897,480 · Granted Nov 5, 2019

Targets of acinetobacter baumannii

Inventors: Simon Urwyler (Bern, CH); Markus Haake (Bern, CH); Michael Rudolf (Ittigen, CH)
A61K39/1045A61K39/104C07K14/212C07K14/22C07K16/1217A61K2039/55555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,463,727
App. No.
15/897,480
Granted
Nov 5, 2019
Kind
B2
Abstract

The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Claims (14)

1. An immunogenic composition comprising:

an isolated polypeptide encoded by a recombinant nucleic acid sequence comprising a polynucleotide sequence having the nucleic acid sequence of:

SEQ ID NO: 15; and,

an immuno-effective amount of an adjuvant;

wherein the polypeptide is isolated by a process comprising (i) providing a host cell transformed/transfected with an expression vector comprising said recombinant nucleic acid sequence, (ii) growing the cell, and (iii) purifying the polypeptide from the cell or the cell's growth environment; and,

wherein the composition is effective in generating an immune response against Acinetobacter baumannii in a subject in need thereof.

2. An immunogenic composition comprising:

an isolated recombinant antigenic polypeptide consisting of the amino acid sequence SEQ ID NO: 16 having immunostimulatory activity in combination with an immuno-effective amount of an adjuvant; and,

one or more polypeptides selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, and 14.

3. The composition according to claim 1 , further comprising an effectively immunogenic delivery vehicle.

4. The composition according to claim 1 , wherein the adjuvant is selected from the group consisting of: virosomes, Freund's adjuvants (complete and incomplete), Gerbu adjuvant, mycobacteria, cholera toxin, tetanus toxoid, E. coli heat-labile toxin, quil-saponin mixtures, MF59, MALP-2, ISCOMs, aluminum hydroxide, aluminum phosphate, calcium phosphate, lysolecithin, pluronic polyols, polyanions, peptides, keyhole limpet hemocyanins, dinitrophenol, saponins, muramyl dipeptides, CpG dinucleotides, CpG oligonucleotides, monophosphoryl lipid A, polyphosphazenes, virus-like particles, and cochleates.

5. The composition according to claim 1 , wherein the recombinant nucleic acid sequence further comprises a sequence encoding a His tag.

6. The composition of claim 1 , further comprising one or more polypeptides selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, and 14.

7. The composition of claim 1 , wherein the composition does not comprise any additional Acinetobacter baumannii polypeptides.

Assignments (2)
SECURITY INTEREST Recorded Jun 21, 2023
From: ARIDIS PHARMACEUTICALS, INC.; ARIDIS BIOPHARMACEUTICALS, LLC; ARIDIS PHARMACEUTICALS, C.V.
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 064020/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2023
From: URWYLER, SIMON; HAAKE, MARKUS; RUDOLF, DR. MICHAEL
To: ARIDIS PHARMACEUTICALS, INC.
Reel/Frame 063207/0111 →
Priority Claims (1)
EP 11191320 · Nov 30, 2011 · regional
Continuity (3)
Division 15427976 · Feb 8, 2017
Division 14362058
Related Publication 20180214535A1 · Aug 2, 2018